AzTrials
AzTrials

Environmental Enteric DysfunctionNCT04275167

Capsule Endomicroscopy for Visualization of the Small Intestine in EED Population in Pakistan

A study testing Tethered Capsule Endomicroscope/Trans Nasal Endomicroscope in people with Environmental Enteric Dysfunction, run by Massachusetts General Hospital at 1 site in Pakistan.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

This pilot study will test the feasibility and tolerability of the tethered OCT capsule and Trans Nasal Endomicroscopy probe and accessory devices for imaging the small intestine in subjects with EED and a matched non-EED cohort. Read more about this study

Who is it for?
Ages 6 months to 70 yearsHealthy volunteers can take part
Conditions the study is for
Environmental Enteric Dysfunction
What is being tested?
Tethered Capsule Endomicroscope/Trans Nasal Endomicroscope
Could I receive a placebo?
No, everyone receives an active treatment
How many people
170 participants
Where
1 sitePakistan
Study dates
11 Oct 2017to Jan 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 months to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Participants 18 years and older
  • Participants who are in their 2nd trimester of singleton pregnancy as confirmed by an ultrasound
  • Participants with a BMI below 18.5 without clear etiology and healthy pregnant women with BMI between 18.5 -24.5.
  • Participants must be able to follow fasting instructions prior to the procedure
  • Participants must be able to consent to the procedure
  • Tethered Capsule Exclusion Criteria:
Show all 31Show fewer
  • Participants with any history of esophageal or intestinal strictures or prior GI surgery
  • Participants with history of pyloric stenosis
  • Participants with HIV diagnosis
  • Trans Nasal Exclusion Criteria:
  • Participants with any contraindications for NG/NJ tube placement, including but not limited to those listed below:
  • Participants with any history of esophageal or intestinal strictures or prior GI surgery
  • Participants with history of pyloric stenosis or atresia
  • Participants with suspected or diagnosed HIV, Hepatitis B and C
  • Participants with any history of esophageal or intestinal strictures or prior GI surgery
  • Participants with a history of upper gastrointestinal surgery including fundoplication
  • Participants with upper GI obstruction
  • Participants with short bowel syndrome
  • Participants with upper respiratory infection at least 7 days prior to the procedure
  • Deviated septum or any other anatomical abnormalities of the nasopharynx or upper gastrointestinal region, history of trans-sphenoidal surgery, facial or cranial trauma and fractures, chronic sinusitis, esophageal strictures, varices etc.
  • Participants on drugs which impair clotting like anticoagulants and antiplatelet drugs, NSAIDS, history of bleeding disorders.
  • Participants with upper GI bleeding
  • Microbiome Brush Exclusion Criteria
  • Participants with any contraindications to gastrointestinal biopsies as per standard of care
  • For pregnant participants:
  • Participants with high-risk pregnancy conditions at the discretion of the subject's physician and the PI
  • Pregnant participants with a history of hyperemesis gravidarum
  • Pregnant participants with a history of severe anemia
  • Pregnant participants with gestational thrombocytopenia
  • Pregnant participants with Type 1 diabetes
  • Pregnant participants with Type 2 diabetes on medication and gestational diabetes requiring medication

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Pakistan1 site
  • Aga Khan Medical Center

    Karachi

Other trials in Pakistan

About this study

This pilot study will test the feasibility and tolerability of the tethered OCT capsule and Trans Nasal Endomicroscopy probe and accessory devices for imaging the small intestine in subjects with EED and a matched non-EED cohort. This study will assess subject tolerability, optimal imaging technique, and imaging of EED features.

Read the detailed description

Environmental enteric dysfunction (EED) is a poorly understood condition characterized by intestinal inflammation and loss of barrier function that is prevalent in regions of the world with inadequate sanitation and hygiene. EED is a major driver of malnourishment, poor neurological development, stunting, oral vaccine failure, and infection, affecting 25% of all children globally and causing over a million deaths each year . It is hypothesized that the stunting associated with EED begins in utero and that the mother's gut health has a significant impact on the fetus. Key periods of growth from pregnancy through birth and childhood offer windows for potential intervention Progress towards understanding EED and developing effective interventions has been hampered by an inability to evaluate the intestinal mucosa of populations in impoverished regions of the world where this condition is endemic.

The Tearney Laboratory has developed a minimally invasive screening method known as tethered capsule endomicroscopy (TCE) for imaging intestinal mucosa. With TCE, an unsedated subject swallows a tethered pill, which captures microscopic images of the entire esophagus, stomach, and small intestine, as it is naturally transits these organs via peristalsis and under the influence of gravity. The capsule implements a microscopic imaging technology called optical coherence tomography (OCT) that obtains 10-µm-resolution cross-sectional images of tissue. The procedure is brief, well tolerated, and can be much less expensive than endoscopy. The Investigators have implemented TCE for imaging the upper gastrointestinal tract of adults and adolescents with Celiac Disease (CD) and eosinophilic esophagitis (EoE), inflammatory conditions that are common in the US. The qualities seen thus far in their TCE studies - high imaging resolution, comprehensive tissue assessment, and minimal invasiveness - are also the qualities needed for evaluating the intestinal mucosa in populations with EED.

The Tearney Lab has also developed a new technique of deployment, Trans Nasal Endomicroscopy (TNE). The TNE catheter comprises of an introduction tube, similar to a standard Nasojejunal tube, with one or two balloons attached at the distal end. These balloons are inflated with Galinstan , a safe liquid metal alloy used in pediatric thermometers, or saline or sugar water or air which provides weight for the device to move to the duodenum under the forces of gravity and peristalsis. The TNE catheter encloses the OCT optics within, and is designed to have many of the same imaging properties of TCE but is introduced Trans nasally so that it can be effectively used in children, infants and also enable collection of various tissue samples using accessory probes for analysis through the lumen of the introduction tube.

There have been theories proposed that increased microorganism load and/or dysbiosis or an imbalance in the composition of gut microorganisms in the intestine may be important in the establishment and/or maintenance of EED. Duodenal Aspiration during endoscopy is currently used as gold standard for standard of care to collect targeted microbiome. However, the microbiome yield from this procedure is low and the procedure requires an EGD, which is a fairly invasive procedure, and carries all of the risks associated with an EGD . Tearney lab has developed a brush that can collect microbiota samples from the small intestine, in the unsedated subject in a non-invasive manner. The brush is similar to cytology brush used in standard clinical care, designed to be deployed through the TNIT tube.

The first phase of this study will test the feasibility and tolerability of the TCE device for imaging subjects with EED. The second phase of this study will test the TNE device and its accessories for imaging and microbial sample collection in pregnant women.

Being tested
Tethered Capsule Endomicroscope/Trans Nasal Endomicroscope
Keywords
Tethered Capsule Endomicroscopy, Optical Coherence Tomography, EED, Pakistan, Intestinal Disorder
Medical subject headings
Intestinal Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tethered Capsule Endomicroscope/Trans Nasal EndomicroscopeDevice

    Either the Tethered Capsule Endomicroscope or the Transnasal Endomicroscope will be deployed in the subject. Once the capsule is swallowed /TNE device is inserted, the device will naturally be moved to the duodenum via peristalsis. Once in the duodenum, imaging will be performed. For subjects receiving the TNE device, brushing samples will be collected through the introduction tube.

Study groups in NCT04275167
Study groupRoleWhat they receive
Feasibility of TCEExperimentalFeasibility is measured by the number of participants that we have successfully deployed the Tethered capsule device in.
Receives: Device: Tethered Capsule Endomicroscope/Trans Nasal Endomicroscope
Feasibility of TNE and Microbiome BrushingExperimentalFeasibility is measured by the number of participants that we have successfully deployed the TNE device and collected brush samples in.
Receives: Device: Tethered Capsule Endomicroscope/Trans Nasal Endomicroscope

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Feasibility of TCE and TNE

    Number of participants that we have successfully deployed the Trans-nasal imaging device/Tethered capsule device in.

    Measured: up to 3 hours during the study.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Feb 2020
  2. Study start11 Oct 2017
  3. Primary completionJan 2028 (estimated)
  4. Study completionJan 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Device feasibility
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
170 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04275167
Sponsor's protocol ID
2017P001219
Status last verified
Jan 2026
First submitted
9 Dec 2019
Last updated
14 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Tethered Capsule Endomicroscope/Trans Nasal Endomicroscope in people with Environmental Enteric Dysfunction, run by Massachusetts General Hospital at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 31 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 14 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Feasibility of TCE and TNE (time frame: up to 3 hours during the study.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in